Tradestie Institutional Equity Comparison Engine
BNTC vs EYEG โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EYEG Overall Edge
EYEG Captures Institutional Edge (2โ1 Pillars ยท 3โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to EYEG (EYEG) driven by superior Momentum & Technical, Options & Structure while BNTC counters with relative strength in Growth & Margin. Fundamentally, BNTC trades at N/M Forward P/E with 0.0% operating margin (+12.5% YoY revenue) versus EYEG at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BNTC sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against EYEG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BNTC N/M vs EYEG N/M Fwd P/E
Growth & Margin Winner
BNTC
Op Margin 0.0% vs N/A ยท YoY +12.5% vs N/A
Momentum & Technical Winner
EYEG
1Y -39.6% vs -6.4% ยท 52W Pos 3% vs 15%
Options & Structure Winner
EYEG
BREAKDOWN (6th %ile IV) vs UNCLASSIFIED (N/A IV)
BNTC
NASDAQ
Benitec Biopharma Inc. Common Stock
Pharmaceutical Preparations
$7.92
-2.76% 1D
Market Cap
$294.0M
1M Return
-10.26%
1Y Return
-39.58%
Forward P/E
N/M
Unified AI Score
40.8 / 100
SELL
Tech 28.0
Fund 50.0
Flow 63.0
Mom 64.0
EYEG
US Equity
EYEG
Institutional Equity
$33.73
+0.48% 1D
Market Cap
N/A
1M Return
+0.42%
1Y Return
-6.36%
Forward P/E
N/M
Unified AI Score
55.0 / 100
HOLD
Tech 73.0
Fund 61.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BNTC -39.58%
EYEG -6.36%
Spread: +33.71 pp (EYEG Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BNTC TTM Op. Margin: 0.0%
EYEG TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BNTC vs EYEG. Trailing 12-month operating profitability (BNTC 0.0% vs EYEG N/A) and valuation multiples (BNTC N/M vs EYEG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BNTC | EYEG | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $294.0M | N/A | Larger Scale | BNTC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +12.5% | N/A | Higher Growth | BNTC |
| Operating Margin (TTM) Profitability | 0.0% | N/A | Higher Margin | BNTC |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | BNTC |
| Return on Equity (ROE) Capital Efficiency | -37.6% | N/A | Higher ROE | BNTC |
| 52-Week Range Position Momentum | 3% ($8โ$14) | 15% ($33โ$36) | Stronger Trend | EYEG |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 70% Vol | 0.13ฮฒ ยท 5% Vol | Lower Realized Risk | EYEG |
| Unified Institutional Score Composite Signal | 40.8 / 100 (SELL) | 55.0 / 100 (HOLD) | Higher Composite | EYEG |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BNTC vs EYEG Buy Guide
BNTC
BREAKDOWN
151d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
EYEG
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BNTC nor EYEG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.